drugset / Trial / NCT00457951

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951 ↗

Phase 2 Terminated 158 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.

Timeline

Start
2007-04
Primary completion
2009-08
Completion
2009-10

Outcome

Outcome not reported

Stopped: “Interim analysis: safety without efficacy ODSH in patients with acute COPD.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ODSH Unknown 0.375 mg/kg Intravenous